Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Inclusion Criteria: * 18 years of age or older * Histologically documented diagnosis of mucosal melanoma or acral melanoma or chronically sun damaged melanoma as evidenced by solar elastosis on pathology * Patient's tumor with evidence for KIT mutation or amplification. Patient tumors that already have documented mutations or amplification do not have to have tissue submitted again for analysis to confirm eligibility * Have failed, progressed, or not been able to tolerate other tyrosine kinase inhibitors including but not limited to imatinib mesylate, sunitinib or dasatinib treatment. * At least one measurable site of disease * ECOG Performance Status 0, 1 or 2 * Adequate organ function as outlined in the protocol * Negative pregnancy test for female patients of childbearing potential Exclusion Criteria: * Patient has received any other investigational agents within 28 days of first day of study drug dosing unless the disease is rapidly progressing * Patient is \< 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ * Female patients who are pregnant or breast-feeding * Patient has a severe and/or uncontrolled medical disease * Patient has a rare hereditary problem of galactose intolerance, severe lactase deficiency or of glucose-galactose malabsorption * Patient with electrolyte abnormality unless the level can be corrected to normal levels prior to initiating study drug * Known brain metastasis * Known chronic liver disease * Patient has received chemotherapy within 4 weeks prior to study entry, unless the disease is rapidly progressing (6 weeks for nitrosourea or mitomycin-C) * Patient previously received radiotherapy to 25% or greater of the bone marrow * Patient had a major surgery within 2 weeks prior to study entry * Impaired cardiac function * QTc \> 450msec on screening ECG * Myocardial infarction within one year prior to starting nilotinib * Other clinically significant heart disease * Patients who are currently receiving treatment with any of the medications that have the potential to prolong QT interval * Patients who are currently receiving Warfarin \> 1mg/day * Patient with any significant history of non-compliance to medical regimens or with the inability to grant reliable informed consent * Prior therapy with nilotinib